Open access
Sep 2026
Evaluation of Radiation Safety of Radiopharmaceutical Based on 177Lu-Dota-PSMA in the Treatment of Metastatic Castration-Resistant Prostate Cancer
When treating patients diagnosed with metastatic castration-resistant prostate cancer with 177Lu-DOTA-PSMA, the absorbed dose in the red bone marrow may exceed the established safe limit of 2 Gy in a significant proportion of patients.
I. Khvostunov, V. Krylov, A. Shurinov et al.
· Medical Radiology and radiat... · 0 citations